Literature DB >> 20308302

Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis.

Giovanni Di Bonaventura1, Arianna Pompilio, Roberta Zappacosta, Francesca Petrucci, Ersilia Fiscarelli, Cosmo Rossi, Raffaele Piccolomini.   

Abstract

Stenotrophomonas maltophilia is a pathogen that causes infections mainly in immunocompromised patients. Despite increased S. maltophilia isolation from respiratory specimens of patients with cystic fibrosis (CF), the real contribution of the microorganism to CF pathogenesis still needs to be clarified. The aim of the present study was to evaluate the pathogenic role of S. maltophilia in CF patients by using a model of acute respiratory infection in DBA/2 mice following a single exposure to aerosolized bacteria. The pulmonary bacterial load was stable until day 3 and then decreased significantly from day 3 through day 14, when the bacterial load became undetectable in all infected mice. Infection disseminated in most mice, although at a very low level. Severe effects (swollen lungs, large atelectasis, pleural adhesion, and hemorrhages) of lung pathology were observed on days 3, 7, and 14. The clearance of S. maltophilia observed in DBA/2 mouse lungs was clearly associated with an early and intense bronchial and alveolar inflammatory response, which is mediated primarily by neutrophils. Significantly higher levels of interleukin-1beta (IL-1beta), IL-6, IL-12, gamma interferon (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), GROalpha/KC, MCP-1/JE, MCP-5, macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-2, and TARC were observed in infected mice on day 1 with respect to controls. Excessive pulmonary infection and inflammation caused systemic effects, manifested by weight loss, and finally caused a high mortality rate. Taken together, our results show that S. maltophilia is not just a bystander in CF patients but has the potential to contribute to the inflammatory process that compromises respiratory function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308302      PMCID: PMC2876550          DOI: 10.1128/IAI.01391-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Trimethoprim-sulfamethoxazole in the treatment of Stenotrophomonas maltophilia osteomyelitis.

Authors:  Michael L Landrum; Nicholas G Conger; Michael A Forgione
Journal:  Clin Infect Dis       Date:  2005-05-15       Impact factor: 9.079

2.  Pseudomonas aeruginosa exoenzyme S stimulates murine lymphocyte proliferation in vitro.

Authors:  N G Barclay; J C Spurrell; T F Bruno; D G Storey; D E Woods; C H Mody
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection.

Authors:  J C Boucher; H Yu; M H Mudd; V Deretic
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

4.  A murine model for infection with Burkholderia cepacia with sustained persistence in the spleen.

Authors:  D P Speert; B Steen; K Halsey; E Kwan
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

5.  Acute necrotizing ulcerative gingivitis and bacteremia caused by Stenotrophomonas maltophilia in an immunocompromised host.

Authors:  Isao Miyairi; Jeremy A Franklin; Martin Andreansky; Katherine M Knapp; Randall T Hayden
Journal:  Pediatr Infect Dis J       Date:  2005-02       Impact factor: 2.129

6.  Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.

Authors:  A M Jones; M E Dodd; J R W Govan; V Barcus; C J Doherty; J Morris; A K Webb
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

7.  Prospective evaluation of emerging bacteria in cystic fibrosis.

Authors:  G Steinkamp; B Wiedemann; E Rietschel; A Krahl; J Gielen; H Bärmeier; F Ratjen
Journal:  J Cyst Fibros       Date:  2005-03       Impact factor: 5.482

8.  Alcaligenes infection in cystic fibrosis.

Authors:  Kenneth Tan; Steven P Conway; Keith G Brownlee; Christine Etherington; Daniel G Peckham
Journal:  Pediatr Pulmonol       Date:  2002-08

9.  Microbiology of sputum from patients at cystic fibrosis centers in the United States.

Authors:  J L Burns; J Emerson; J R Stapp; D L Yim; J Krzewinski; L Louden; B W Ramsey; C R Clausen
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

10.  Microbiology of airway disease in a cohort of patients with cystic fibrosis.

Authors:  Antonietta Lambiase; Valeria Raia; Mariassunta Del Pezzo; Angela Sepe; Vincenzo Carnovale; Fabio Rossano
Journal:  BMC Infect Dis       Date:  2006-01-11       Impact factor: 3.090

View more
  30 in total

1.  Stenotrophomonas maltophilia Encodes a VirB/VirD4 Type IV Secretion System That Modulates Apoptosis in Human Cells and Promotes Competition against Heterologous Bacteria, Including Pseudomonas aeruginosa.

Authors:  Megan Y Nas; Richard C White; Ashley L DuMont; Alberto E Lopez; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2019-08-21       Impact factor: 3.441

2.  Type II Secretion-Dependent Degradative and Cytotoxic Activities Mediated by Stenotrophomonas maltophilia Serine Proteases StmPr1 and StmPr2.

Authors:  Ashley L DuMont; Sara M Karaba; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

3.  Stenotrophomonas maltophilia Differential Gene Expression in Synthetic Cystic Fibrosis Sputum Reveals Shared and Cystic Fibrosis Strain-Specific Responses to the Sputum Environment.

Authors:  Graham G Willsey; Korin Eckstrom; Annette E LaBauve; Lauren A Hinkel; Kristin Schutz; Robert J Meagher; John J LiPuma; Matthew J Wargo
Journal:  J Bacteriol       Date:  2019-07-10       Impact factor: 3.490

4.  Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections.

Authors:  Melissa S McDaniel; Trenton Schoeb; W Edward Swords
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

5.  Structure of aminodeoxychorismate synthase from Stenotrophomonas maltophilia.

Authors:  Asim K Bera; Vesna Atanasova; Anjali Dhanda; Jane E Ladner; James F Parsons
Journal:  Biochemistry       Date:  2012-12-11       Impact factor: 3.162

Review 6.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

7.  Stenotrophomonas maltophilia strains replicate and persist in the murine lung, but to significantly different degrees.

Authors:  Ruella Rouf; Sara M Karaba; Jenny Dao; Nicholas P Cianciotto
Journal:  Microbiology (Reading)       Date:  2011-05-05       Impact factor: 2.777

8.  Genetic susceptibility to toxicologic lung responses among inbred mouse strains following exposure to carbon nanotubes and profiling of underlying gene networks.

Authors:  Evan A Frank; Vinicius S Carreira; Kumar Shanmukhappa; Mario Medvedovic; Daniel R Prows; Jagjit S Yadav
Journal:  Toxicol Appl Pharmacol       Date:  2017-04-19       Impact factor: 4.219

9.  Stenotrophomonas maltophilia encodes a type II protein secretion system that promotes detrimental effects on lung epithelial cells.

Authors:  Sara M Karaba; Richard C White; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

10.  Functional characterization of the RNA chaperone Hfq in the opportunistic human pathogen Stenotrophomonas maltophilia.

Authors:  Emanuela Roscetto; Tiziana Angrisano; Valerio Costa; Mariassunta Casalino; Konrad U Förstner; Cynthia M Sharma; Pier Paolo Di Nocera; Eliana De Gregorio
Journal:  J Bacteriol       Date:  2012-08-24       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.